Updated ASCO guidelines for non-castrate, recurrent, advanced, or metastatic prostate cancer focus on data from the PEACE-1, ARASENS, ENZAMET and ARCHES trials. “The major reason for the update to the 2021 ASCO guidelines on the initial management...